Abstract 1580
Background
Brain metastases (BMs) account for a relatively large proportion of patients with metastatic non-small cell lung cancer (NSCLC) both at the time of diagnosis and during the course of disease, which is a major cause leading to a significant increase in cancer-related mortality for NSCLC patients. We aimed to build a novel risk classification system to predict overall survival (OS) of patients presenting with BMs at the first diagnosis of NSCLC.
Methods
Data on NSCLC patients with BMs was extracted from the SEER database between 2010 and 2013. All cases were randomly divided into the training cohort and validation cohort (7:3). Cox regression was performed to select the independent predictors of OS. A nomogram was established for predicting 6-, 12- and 18-month OS. The prognostic performance of nomogram was evaluated using concordance indexes (C-indexes), calibration curves, and decision curve analyses (DCAs). All statistical analysis was performed with R software.
Results
According to the multivariate Cox regression of the training set, the following variables were contained in the nomogram prognostic model: age, marital status, sex, race, primary site, histological type, T stage, N stage, metastatic pattern, whether received radiotherapy and chemotherapy. The nomogram displayed good accuracy in predicting 6, 12 and 18 months OS. The C-indexes of training set and validation set were 0.729 and 0.723, respectively. The calibration curves showed excellent consistency between the actual results and the nomogram prediction, and the DCAs exhibited great clinical utility of the model. A new risk classification system based on nomogram scores was introduced to classify NSCLC patients with BMs into three subgroups. In the training cohort, the median OS of patients in the low-, intermediate- and high-risk groups was 11.0 months (95% confidence interval [CI] 10.3–11.7), 5.0 months (95% CI 4.6–5.4), and 2.0 months (95% CI 1.9–2.1), respectively.
Conclusions
We established a risk stratification system based on nomogram scores to predict the OS of patients presenting with BMs at initial diagnosis of NSCLC. These predictive models can act as auxiliary tools to guide treatment strategies and prognostic evaluation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2935 - Correlation of progression free survival-2 and overall survival in solid tumors
Presenter: Paul Mainwaring
Session: Poster Display session 1
Resources:
Abstract
2273 - High performance of serial tumor biopsies in first in human (FIH) phase I trials.
Presenter: Jun Sato
Session: Poster Display session 1
Resources:
Abstract
5933 - Response rates and lesion-level progression patterns of solid tumor patients in an academic phase 1 program: implications for tumor heterogeneity
Presenter: Christopher Chen
Session: Poster Display session 1
Resources:
Abstract
3569 - Clinical Benefit and Response Rate in Early Phase Clinical Trials: First Report from a Single-Institution Study
Presenter: Antonio Marra
Session: Poster Display session 1
Resources:
Abstract
4139 - Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): a single Phase I Unit experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract
4451 - Improving patient selection for immuno-oncology phase 1 trials: an external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O).
Presenter: Ghassan Al Darazi
Session: Poster Display session 1
Resources:
Abstract
1696 - Demonstrating the Changing Trends in Phase 1 Clinical Trials
Presenter: Christina Guo
Session: Poster Display session 1
Resources:
Abstract
3202 - Participation of Women in phase 1 oncology clinical trials
Presenter: Laura Vidal
Session: Poster Display session 1
Resources:
Abstract
4518 - Predictors for early trial discontinuation of patients with cancer participating in phase I clinical trials
Presenter: Joeri Douma
Session: Poster Display session 1
Resources:
Abstract
4368 - Safety of Tumor Treating Fields delivery to the torso: Meta analysis from TTFields clinical trials
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract